30 closest matches · ranked by relevance
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Were Alive at 1 Year Transplant Overall Survival — 130 Participants
Advanced Hematologic Malignancies · Leukemia · Preleukemia
Primary: Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation — 48; 30 participants
Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Number of Participants Who Were Alive at 1 Year Post Transplant — 59; 40; 1; 26 Participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS) · Hematopoietic Stem Cell Transplant (HSCT)
Primary: Number of Non-relapsed Deaths by 100 Days Post-transplant in Pediatric Patients Receiving a Myeloablative or Reduced-intensity Preparative Regimen Prior to HSCT for…
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Acute Myeloid Leukemia/Transient Myeloproliferative Disorder · Adult Acute Myeloid Leukemia in Remission
Primary: Overall Survival — 6; 6 participants
Acute Myeloid Leukemia · Acute Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants With Engraftment. — 18; 12 participants
Leukemia
Primary: Cytoreductive Response — 52 percentage of participants
Hematologic Malignancies · Disorder Related to Transplantation · Hematopoietic Malignancy
Primary: Event Free Survival (EFS) for Research Participants — 4 Participants
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Blood Cancer · Multiple Myeloma
Primary: Event-free Survival (EFS) — 0; 24; 24 Participants
Myeloablative Conditioning · HLA-mismatched Bone Marrow Transplantation · Graft Survival
Primary: Cumulative Incidence of Non-relapse Mortality — 0 percent
Anemia, Aplastic
Primary: Disease-free Survival (DFS) — 6; 3; 9; 4 participants
Chronic Leukemia · Acute Leukemia · Hodgkin's Disease
Primary: Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant — 30 percentage of patients
Multiple Myeloma
Primary: To Estimate the Response at Day 100 Following Transplant (Rate of CR) — 26; 32; 7 Participants
Myelodysplastic Syndromes · Myeloproliferative Disorders · Leukemia, Lymphocytic
Primary: Non-relapse Mortality — 3; 4; 2 participants — p=.07
Leukemia · Lymphoma · Myeloma
Primary: Maximum Tolerated Dose — 6800 mmol-min/L
Myeloid Hematological Malignancies
Primary: Overall Survival at 100 Days, 1 Year, and 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients. — 0.923; 0.923; 0.923 probability of overall survival
Hematological Malignancies
Primary: Percentage of Participants With Grade II-IV Acute GVHD Between the 2 Groups — 12.2; 8.9 percentage of participants with aGVHD — p=0.508
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 5; 3; 10; 17 participants
Multiple Myeloma · Lymphoma
Primary: Average Overall Survival Time — 3 years
Leukemia, Erythroblastic, Acute · Myelodysplastic Syndromes
Primary: Disease Free Survival at 1 Year Post-transplant — 18 Participants
Acute Leukemia · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia/Lymphoma
Primary: Probability of Acute Graft Versus Host Disease (GVHD) — 0; 30 Percent of participants
Bone Marrow Failure Syndromes · Immunodeficiencies · Immune Dysregulation Syndromes
Primary: Number of Participants With Engraftment — 2 Participants
Lymphoma · Myeloma · Leukemia
Primary: Toxicity — 21; 25 participants
Hematologic Malignancies
Primary: Disease-free Survival (DFS) — 57; 29; 38; 57 percentage of participants
Severe Thalassemia
Primary: Primary Objective: Event-free Survival at 1 Year. — 17 Participants
Myelofibrosis
Primary: The Primary Endpoint is Progression-free Survival. — 24; 11 participants
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-free Survival Rate — 48.8; 61.8 percent probability — p=0.0082
Leukemia · Acute Myeloid Leukemia · Acute Lymphocytic Leukemia
Primary: Non-Relapse Mortality Rate (NRM) — 2; 8 Participants